Nora Hilda Rosas-Murrieta

Prof. Dr. Nora Hilda Rosas-Murrieta

Instituto de Ciencias, Benemérita Universidad Autonoma de Puebla, Puebla, Mexico
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Life Sciences
Verified
Journal Article
Closed access
FSFabiola Lilí Sarmiento-Salinas
Fabiola Lilí Sarmiento-Salinas
APAndrea Perez-Gonzalez
Andrea Perez-Gonzalez
AAAdilene Acosta-Casique
Adilene Acosta-Casique
AIAdrián Ix-Ballote
Adrián Ix-Ballote
ADAlfonso Diaz
Alfonso Diaz
Paola MaycottePaola Maycotte
Paola Maycotte

Verified
Journal Article
Open access
PDF file
NMNancy Martínez-Montiel
Nancy Martínez-Montiel
Nora Hilda Rosas-MurrietaNora Hilda Rosas-Murrieta
Nora Hilda Rosas-Murrieta
MAMaricruz Anaya-Ruiz
Maricruz Anaya-Ruiz
EMEduardo Monjaraz-Guzman
Eduardo Monjaraz-Guzman
RMRebeca Martinez-Contreras
Rebeca Martinez-Contreras
Alternative splicing is a key mechanism determinant for gene expression in metazoan. During alternative splicing, non-coding sequences are removed to generate different mature messenger RNAs due to a combination of sequence elements and cellular factors that contribute to splicing regulation. A different combination of splicing sites, exonic or intronic sequences, mutually exclusive exons or retained introns could be selected during alternative splicing to generate different mature mRNAs that could in turn produce distinct protein products. Alternative splicing is the main source of protein diversity responsible for 90% of human gene expression, and it has recently become a hallmark for cancer with a full potential as a prognostic and therapeutic tool. Currently, more than 15,000 alternative splicing events have been associated to different aspects of cancer biology, including cell proliferation and invasion, apoptosis resistance and susceptibility to different chemotherapeutic drugs. Here, we present well established and newly discovered splicing events that occur in different cancer-related genes, their modification by several approaches and the current status of key tools developed to target alternative splicing with diagnostic and therapeutic purposes.

28 September 2015 in Virology Journal
Verified
Journal Article
Open access
PDF file
HPHelen K. Palma-Ocampo
Helen K. Palma-Ocampo
JFJuan C. Flores-Alonso
Juan C. Flores-Alonso
VVVerónica Vallejo-Ruiz
Verónica Vallejo-Ruiz
JRJulio Reyes-Leyva
Julio Reyes-Leyva
LFLilian Karem Flores-Mendoza
Lilian Karem Flores-Mendoza
Gerardo Santos-LopezGerardo Santos-Lopez
Gerardo Santos-Lopez
In viral disease, infection is controlled at the cellular level by type I interferon (IFN-I), but dengue virus (DENV) has the ability to inhibit this response. Type III interferon, also known as lambda IFN (IFN-III or IFN-λ), is a complementary pathway to the antiviral response by IFN-I. This work analyzed the IFN-λ (IFN-III) mediated antiviral response against DENV serotype 2 (DENV-2) infection. Dengue fever patients were sampled to determine their IFN-λ levels by ELISA. To study the IFN-λ response during DENV infection we selected the epithelial cell line C33-A, and we demonstrated that it is permissive to DENV-2 infection. The effect of IFN-λ on virus replication was determined in these cells, in parallel to the expression of IFN-stimulated genes (ISGs), and Suppressor of Cytokine Signaling (SOCS), genes measured by RT-qPCR. We found increased (~1.8 times) serological IFN-λ in dengue fever patients compared to healthy blood donors. IFN-λ inhibited DENV-2 replication in a dose-dependent manner in vitro. The reduction of viral titer corresponded with increased ISG mRNA levels (MX1 and OAS1), with the highest inhibition occurring at ISG’s peak expression. Presence of IFN-negative regulators, SOCS1 and SOCS3, during DENV-2 infection was associated with reduced IFN-λ1 expression. Evidence described here suggests that IFN-λ is a good candidate inhibitor of viral replication in dengue infection. Mechanisms for the cellular and organismal interplay between DENV and IFN- λ need to be further studied as they could provide insights into strategies to treat this disease. Furthermore, we report a novel epithelial model to study dengue infection in vitro.

16 March 2018 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
MFMaría R. Flores-Ocelotl
María R. Flores-Ocelotl
Nora Hilda Rosas-MurrietaNora Hilda Rosas-Murrieta
Nora Hilda Rosas-Murrieta
Diego A. Moreno-FernandezDiego A. Moreno-Fernandez
Diego A. Moreno-Fernandez
VVVerónica Vallejo-Ruiz
Verónica Vallejo-Ruiz
JRJulio Reyes-Leyva
Julio Reyes-Leyva
Gerardo Santos-LopezGerardo Santos-Lopez
Gerardo Santos-Lopez
Urtica dioica, Taraxacum officinale, Calea integrifolia and Caesalpinia pulcherrima are widely used all over the world for treatment of different illnesses. In Mexico, these plants are traditionally used to alleviate or counteract rheumatism and inflammatory muscle diseases. In the present study we evaluated the activity of aqueous and methanolic extracts of these four plants, on the replication of dengue virus serotype 2 (DENV2). Extraction process was carried out in a Soxtherm® system at 60, 85 and 120 °C; a chemical fractionation in silica gel chromatography was performed and compounds present in the active fractions were identified by HPLC-DAD-ESI/MSn. The cytotoxic concentration and the inhibitory effect of extracts or fractions on the DENV2 replication were analyzed in the BHK-21 cell line (plaque forming assay). The half maximal inhibitory concentration (IC50) and the selectivity index (SI) were calculated for the extracts and fractions. The methanolic extracts at 60 °C of T. officinale and U. dioica showed the higher inhibitory effects on DENV2 replication. After the chemical fractionation, the higher activity fraction was found for U. dioica and T. officinale, presenting IC50 values of 165.7 ± 3.85 and 126.1 ± 2.80 μg/ml, respectively; SI values were 5.59 and 6.01 for each fraction. The compounds present in T. officinale, were luteolin and caffeoylquinic acids derivatives and quercertin diclycosides. The compounds in the active fraction of U. dioica, were, chlorogenic acid, quercertin derivatives and flavonol glycosides (quercetin and kaempferol). Two fractions from U. dioica and T. officinale methanolic extracts with anti-dengue activity were found. The compounds present in both fractions were identified, several recognized molecules have demonstrated activity against other viral species. Subsequent biological analysis of the molecules, alone or in combination, contained in the extracts will be carried out to develop therapeutics against DENV2.

16 August 2016 in BioMed Research International
Verified
Journal Article
Open access
PDF file
NMNancy Martínez-Montiel
Nancy Martínez-Montiel
Nora Hilda Rosas-MurrietaNora Hilda Rosas-Murrieta
Nora Hilda Rosas-Murrieta
MMMónica Martínez-Montiel
Mónica Martínez-Montiel
MGMayra Patricia Gaspariano-Cholula
Mayra Patricia Gaspariano-Cholula
RMRebeca Martinez-Contreras
Rebeca Martinez-Contreras
In eukaryotes, genes are frequently interrupted with noncoding sequences named introns. Alternative splicing is a nuclear mechanism by which these introns are removed and flanking coding regions named exons are joined together to generate a message that will be translated in the cytoplasm. This mechanism is catalyzed by a complex machinery known as the spliceosome, which is conformed by more than 300 proteins and ribonucleoproteins that activate and regulate the precision of gene expression when assembled. It has been proposed that several genetic diseases are related to defects in the splicing process, including cancer. For this reason, natural products that show the ability to regulate splicing have attracted enormous attention due to its potential use for cancer treatment. Some microbial metabolites have shown the ability to inhibit gene splicing and the molecular mechanism responsible for this inhibition is being studied for future applications. Here, we summarize the main types of natural products that have been characterized as splicing inhibitors, the recent advances regarding molecular and cellular effects related to these molecules, and the applications reported so far in cancer therapeutics.

9 February 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ARAlan Rodríguez-Enríquez
Alan Rodríguez-Enríquez
IHIrma Herrera-Camacho
Irma Herrera-Camacho
LMLourdes Millán-Pérez-Peña
Lourdes Millán-Pérez-Peña
JRJulio Reyes-Leyva
Julio Reyes-Leyva
Gerardo Santos-LopezGerardo Santos-Lopez
Gerardo Santos-Lopez
Nora Hilda Rosas-MurrietaNora Hilda Rosas-Murrieta
Nora Hilda Rosas-Murrieta
The membrane protein M of the Porcine Epidemic Diarrhea Virus (PEDV) is the most abundant component of the viral envelope. The M protein plays a central role in the morphogenesis and assembly of the virus through protein interactions of the M-M, M-Spike (S) and M-nucleocapsid (N) type. The M protein is known to induce protective antibodies in pigs and to participate in the antagonistic response of the cellular antiviral system coordinated by the type I and type III interferon pathways. The 3D structure of the PEDV M protein is still unknown. The present work exposes a predicted 3D model of the M protein generated using the Robetta protocol. The M protein model is organized into a transmembrane and a globular region. The obtained 3D model of the PEDV M protein was compared with 3D models of the SARS-CoV-2 M protein created using neural networks and with initial machine learning-based models created using trRosetta. The 3D model of the present study predicted four linear B-cell epitopes (RSVNASSGTG and KHGDYSAVSNPSALT peptides are noteworthy), six discontinuous B-cell epitopes, forty weak binding and fourteen strong binding T-cell epitopes in the CV777 M protein. A high degree of conservation of the epitopes predicted in the PEDV M protein was observed among different PEDV strains isolated in different countries. The data suggest that the M protein could be a potential candidate for the development of new treatments or strategies that activate protective cellular mechanisms against viral diseases.